<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01672073</url>
  </required_header>
  <id_info>
    <org_study_id>PROX005</org_study_id>
    <nct_id>NCT01672073</nct_id>
  </id_info>
  <brief_title>Analysis of the Arterial Pressure Wave Form Through the Proxima Device</brief_title>
  <official_title>An Open, Non-randomised, Study to Provide Data on the Arterial Pressure Wave Form Obtained Through the Proxima 3 in Patients Who Require the Insertion of an Arterial Line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sphere Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sphere Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to confirm that the presence of the Proxima 3 disposable in the&#xD;
      arterial line doesn't significantly attenuate the arterial pressure wave form. The principal&#xD;
      aim of the trial will be:&#xD;
&#xD;
      â€¢ To obtain quantitative data allowing investigation of the pressure wave form obtained in a&#xD;
      standard arterial line compared to various arterial lines fitted with the Proxima 3.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to examine the transmission of the arterial pressure wave form&#xD;
      through Proxima 3 disposable attached to a configurable parts of the patient's arterial line.&#xD;
      The Proxima device has been tested by Intertek as part of the Proxima 2 project and found to&#xD;
      comply to BS EN 60601-1 2nd edition &quot;Medical electrical equipment - Part 1: General&#xD;
      requirements for basic safety and essential performance&quot;. Additional internal tests have also&#xD;
      been carried out for clause 51.103, frequency response, from BS EN 60601-2-34(2001).&#xD;
&#xD;
      This study part of the on-going development of the Proxima system which monitors metabolic&#xD;
      parameters in critically ill patients using a disposable sensor array. This study builds upon&#xD;
      the four clinical trials carried out in the past two years by Sphere Medical in partnership&#xD;
      with the NHS (REC references: 10/H1308/53, 10/H0308/113, 11/SW/0166, 12/SW/0175).&#xD;
&#xD;
      This study forms part of the development process for the Proxima family of devices.&#xD;
&#xD;
      The Proxima 3:&#xD;
&#xD;
        -  Is a disposable multi-parameter microanalyser&#xD;
&#xD;
        -  Is connected into the patient's arterial line.&#xD;
&#xD;
        -  Will measure all or some of blood gases, haematocrit and electrolytes and is connected&#xD;
           to a small bedside monitor, which displays the results.&#xD;
&#xD;
        -  Microanalyser can perform an unlimited number of analyses over a period of up to seventy&#xD;
           two hours.&#xD;
&#xD;
        -  Will be used as part of a closed system, reducing infection risk and preventing blood&#xD;
           loss.&#xD;
&#xD;
      Proxima 3 will enable clinicians to measure blood parameters without leaving the patient's&#xD;
      bedside. This will support the ability to respond rapidly to changing conditions in their&#xD;
      critically ill patients. The measurements made by the Proxima 3 system have the potential to&#xD;
      inform clinical decision support systems and to change, at a fundamental level, the ability&#xD;
      of clinicians to improve patient care.&#xD;
&#xD;
      In this study the Proxima 3 is a passive component. It will NOT be connected to the Proxima 3&#xD;
      monitor. NO blood will be taken and NO analysis of the blood analyte concentrations will&#xD;
      occur in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To confirm that siting Proxima 3 in the arterial line does not affect the pressure wave form</measure>
    <time_frame>10 minutes maximum</time_frame>
    <description>The data traces collected from the arterial pressure waveform monitor will undergo quantitative assessment to determine the effect on the pressure wave, if any, by introducing the Proxima 3 device in the system.</description>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Local Pressure Effects</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated in the Intensive Care or High Dependency Units who require an arterial&#xD;
        line to be inserted as standard care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients over the age of 18&#xD;
&#xD;
          -  Patients will give full informed consent to participate in the study before inclusion.&#xD;
&#xD;
          -  All patients who have an arterial line inserted as standard care will be considered&#xD;
             for inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal of consent to participate&#xD;
&#xD;
          -  The patient is considered by the investigator to be unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Clutton-Brock, MB ChB FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Queen Elizabeth Hopsital, Birmingham, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>City and Borough of Birmingham</city>
        <state>Edgbaston</state>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.spheremedical.com</url>
    <description>Click here for more information about this study</description>
  </link>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>August 21, 2012</study_first_submitted>
  <study_first_submitted_qc>August 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2012</study_first_posted>
  <last_update_submitted>August 8, 2013</last_update_submitted>
  <last_update_submitted_qc>August 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pressure</keyword>
  <keyword>waveform</keyword>
  <keyword>arterial</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

